K2 Therapeutics CEO Ying Huang discusses why government investment and US-trained returnees have made China's biotech innovation surge irreversible.
Ying Huang, PhD
Advertisement
Ying Huang, Ph.D., is the Chief Executive Officer and Board Director of K2 Therapeutics, and Strategic Advisor, APAC at MPM BioImpact. He brings over 9 years of experience in research and development at a major pharmaceutical company and 12 years of experience as a biotechnology analyst on Wall Street.
Articles by Ying Huang, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: Amplitude Therapeutics, Chai Discovery Enter Collaborations with Eli Lilly, Bristol Myers Squibb
2
Who Pays for Tariff Driven Input Cost Increases?
3
Pharmaceutical Executive Daily: Amplitude Therapeutics Partners with Eli Lilly
4
The Shift Towards Globally Sourced Innovation
5